**GLP-1 Market Exclusivity Battle: Historical Precedent and Scale** The pharmaceutical litigation over GLP-1 receptor agonists mirrors the cholesterol statin wars of the 1990s-2000s, when patent expiration sparked billions in generic competition and price compression. Novo Nordisk's Ozempic/Wegovy generated $21.2B in 2023 revenue—a trajectory that typically triggers aggressive legal defense once competitors enter. The obesity treatment market is projected to reach $100B+ by 2030, making this dispute a watershed moment: loose IP enforcement could accelerate access but destroy pricing models that fund R&D; tight enforcement preserves innovation incentives but restricts affordable treatment for 42% of Americans classified as obese. This case ultimately determines whether metabolic disorder treatment follows the insulin accessibility crisis (limited during patent protection, democratized after) or the cardiovascular drug model (robust competition enabling broad population treatment).